209 related articles for article (PubMed ID: 36029077)
1. Phytochemicals-based Therapeutics against Alzheimer's Disease: An Update.
Ayaz M; Nawaz A; Naz F; Ullah F; Sadiq A; Islam ZU
Curr Top Med Chem; 2022; 22(22):1811-1820. PubMed ID: 36029077
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective potentials of Lead phytochemicals against Alzheimer's disease with focus on oxidative stress-mediated signaling pathways: Pharmacokinetic challenges, target specificity, clinical trials and future perspectives.
Ayaz M; Mosa OF; Nawaz A; Hamdoon AAE; Elkhalifa MEM; Sadiq A; Ullah F; Ahmed A; Kabra A; Khan H; Murthy HCA
Phytomedicine; 2024 Feb; 124():155272. PubMed ID: 38181530
[TBL] [Abstract][Full Text] [Related]
3. Neuroinflammation in pathogenesis of Alzheimer's disease: Phytochemicals as potential therapeutics.
Vaiserman A; Koliada A; Lushchak O
Mech Ageing Dev; 2020 Jul; 189():111259. PubMed ID: 32450086
[TBL] [Abstract][Full Text] [Related]
4. [Anti-dementia drugs for Alzheimer disease in present and future].
Nabeshima T; Noda Y; Kamei H
Nihon Yakurigaku Zasshi; 2002 Nov; 120(1):24P-29P. PubMed ID: 12491771
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs.
Thakral S; Yadav A; Singh V; Kumar M; Kumar P; Narang R; Sudhakar K; Verma A; Khalilullah H; Jaremko M; Emwas AH
Ageing Res Rev; 2023 Jul; 88():101960. PubMed ID: 37224884
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
[TBL] [Abstract][Full Text] [Related]
7. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
8. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Shimohama S
Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871
[TBL] [Abstract][Full Text] [Related]
9. Determination of Anti-Alzheimer's Disease Activity of Selected Plant Ingredients.
Tuzimski T; Petruczynik A
Molecules; 2022 May; 27(10):. PubMed ID: 35630702
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Sharma P; Tripathi MK; Shrivastava SK
Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
[TBL] [Abstract][Full Text] [Related]
11. Tryptamine: A privileged scaffold for the management of Alzheimer's disease.
Singh YP; Kumar H
Drug Dev Res; 2023 Dec; 84(8):1578-1594. PubMed ID: 37675624
[TBL] [Abstract][Full Text] [Related]
12. Phytoconstituents and their Possible Mechanistic Profile for Alzheimer's Disease - A Literature Review.
Basavan D; Chalichem NSS; Kumar MKS
Curr Drug Targets; 2019; 20(3):263-291. PubMed ID: 30101703
[TBL] [Abstract][Full Text] [Related]
13. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A; Svensson AL
Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
15. Donepezil provides neuroprotective effects against brain injury and Alzheimer's pathology under conditions of cardiac ischemia/reperfusion injury.
Ongnok B; Khuanjing T; Chunchai T; Kerdphoo S; Jaiwongkam T; Chattipakorn N; Chattipakorn SC
Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165975. PubMed ID: 32956775
[TBL] [Abstract][Full Text] [Related]
16. Usmarapride (SUVN-D4010), a 5-HT
Nirogi R; Grandhi VR; Medapati R; Ganuga N; Abraham R; Thentu JB; Palacharla VRC; Petlu S; Srirangavaram M; Subramanian R; Ravella SR; Gagginapally SR; Benade V; Jayarajan P; Mohammed AR
Eur J Pharmacol; 2023 May; 947():175625. PubMed ID: 36997046
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
[TBL] [Abstract][Full Text] [Related]
18. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Robert P
Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
20. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
